Investors call on UnitedHealth to disclose human and economic costs of policies that limit care
Health insurers like UnitedHealth are under tremendous public scrutiny for tactics such as prior authorization and care denials.
Related Articles
In biopharma, mega-deals surged as VCs were more selective
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we…
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
Immunotherapies, specifically monoclonal antibodies targeting the programmed death–1 and programmed death-ligand 1 axis, have rapidly become integral in the management of most patients with early-stage…
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Oncology-focused Postdoctoral Training In Care Delivery and Symptom
Funded by a National Cancer Institute research training grant (1T32CA275764-01A1), the Oncology-focused Postdoctoral Training In Care Delivery and Symptom Science (OPTICS) Training Program at Memorial…
The current landscape of frontline large B-cell lymphoma trials
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
84: My fav lessons from 2024 & what’s next | Happy In Medicine with Dr. Christina Arnold
welcome to our new series on NEW FRAMEWORKS FOR FAST WINS. today we cover my fav lessons from 2024 & what’s next PLUS a fun…
Why scientists say we are fighting H5N1 bird flu with one hand tied behind our backs
When, where and how the H5N1 bird flu virus may evolve and its capacity to spark a pandemic is hard to predict — in part,…
Brief Report: Longitudinal tracking of ALK rearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA
While the administration of tyrosine-kinase inhibitors (TKIs) in ALK rearranged non-small cell lung cancer (NSCLC) has revolutionized precision medicine, detection of gene rearrangements from liquid…
The current landscape of frontline large B-cell lymphoma trials
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
Building the future management of follicular lymphoma with T-cell–redirecting strategies
With the development of chimeric antigen receptor T-cell therapy and biologicals that engage both malignant B cells and normal T cells, the scene is set…